
Peer reviewed version

License (if available):
Unspecified

Link to published version (if available):
10.1152/ajplung.00235.2018

Link to publication record in Explore Bristol Research

PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via APS at https://www.physiology.org/doi/abs/10.1152/ajplung.00235.2018. Please refer to any applicable terms of use of the publisher.

**University of Bristol - Explore Bristol Research**

**General rights**

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Potentiation of the cystic fibrosis transmembrane conductance regulator Cl\(^{-}\) channel by ivacaftor

is temperature-independent

Yiting Wang\(^1\), Zhiwei Cai\(^1\), Martin Gosling\(^2,3\) and David N. Sheppard\(^1\)

\(^1\)School of Physiology, Pharmacology and Neuroscience, University of Bristol,

Biomedical Sciences Building, University Walk, Bristol BS8 1TD, UK,

\(^2\)Enterprise Therapeutics, Sussex Innovation Centre, University of Sussex,

Science Park Square, Brighton BN1 9SB, UK

and

\(^3\)Sussex Drug Discovery Centre, School of Life Sciences, University of Sussex,

Brighton BN1 9QJ, UK

Running Title: Ivacaftor potentiation of CFTR is temperature-independent

Address Correspondence to: D.N. Sheppard, Ph.D.

University of Bristol

School of Physiology, Pharmacology and Neuroscience

Biomedical Sciences Building

University Walk

Bristol BS8 1TD

United Kingdom

Tel: +44 117 331 2290

Fax: +44 117 331 1889

E-mail: D.N.Sheppard@bristol.ac.uk
Ivacaftor is the first drug to target directly defects in the cystic fibrosis transmembrane conductance regulator (CFTR), which cause cystic fibrosis (CF). To understand better how ivacaftor potentiates CFTR channel gating, here we investigated the effects of temperature on its action. As a control, we studied the benzimidazolone UC[CF]-853, which potentiates CFTR by a different mechanism. Using the patch-clamp technique and cells expressing recombinant CFTR, we studied the single-channel behavior of wild-type and F508del-CFTR, the most common CF mutation. Raising the temperature of the intracellular solution from 23 to 37 °C increased the frequency, but reduced the duration of wild-type and F508del-CFTR channel openings. While the open probability (P_o) of wild-type CFTR increased progressively as temperature was elevated, the relationship between P_o and temperature for F508del-CFTR was bell-shaped with a maximum P_o at ~30 °C. For wild-type CFTR and, to a greatly reduced extent, F508del-CFTR, the temperature-dependence of channel gating was asymmetric with the opening rate demonstrating greater temperature sensitivity than the closing rate. At all temperatures tested, ivacaftor and UC[CF]-853 potentiated wild-type and F508del-CFTR. Strikingly, ivacaftor, but not UC[CF]-853, abolished the asymmetric temperature-dependence of CFTR channel gating. At all temperatures tested, P_o values of wild-type CFTR in the presence of ivacaftor were approximately double those of F508del-CFTR, which were equivalent to or greater than those of wild-type CFTR at 37 °C in the absence of the drug. We conclude that the principal effect of ivacaftor is to promote channel opening to abolish the temperature-dependence of CFTR channel gating.

Key words: CFTR chloride ion channel / cystic fibrosis / F508del-CFTR / CFTR potentiation / ivacaftor (VX-770)
INTRODUCTION

The ATP-binding cassette (ABC) transporter cystic fibrosis transmembrane conductance regulator (CFTR; ABCC7) (33, 56) is a ligand-gated anion channel that plays a pivotal role in fluid and electrolyte transport across epithelia (28, 35). The importance of CFTR for epithelial physiology is highlighted by its dysfunction in the common, life-shortening genetic disease cystic fibrosis (55). To date, more than 2,000 mutations have been identified in the CFTR gene (http://www.genet.sickkids.on.ca/app), although most are very rare and not all cause disease. Among those mutations investigated, many disrupt CFTR expression and function by multiple mechanisms (70). This is best illustrated by F508del, the most common CF mutation, a temperature-sensitive folding defect, which not only disrupts the processing and intracellular transport of CFTR, but also destabilizes the protein at the plasma membrane and perturbs channel gating (19, 23, 24, 44).

To restore function to F508del-CFTR, combination therapy with small molecule CFTR correctors and potentiators is required (39, 50). Based on its mechanism of dysfunction (45), multiple CFTR correctors will likely be required to repair misfolding of nucleotide-binding domain 1 (NBD1) and restore correct domain assembly (52), leading to the delivery of F508del-CFTR to the plasma membrane. Once F508del-CFTR is activated by phosphorylated with protein kinase A (PKA), CFTR potentiators increase the frequency and/or duration of channel openings by modifying ATP-dependent or ATP-independent channel gating (15, 26, 37). To date, one CFTR potentiator, ivacaftor (VX-770; Vertex Pharmaceuticals) has been approved for patient use (54, 67). Ivacaftor treatment of CF patients with the gating mutation G551D achieves sustained, long-term clinical benefit, including slower lung function decline and improved nutrition (59). In combination with the CFTR corrector lumacaftor, ivacaftor also has clinical benefit for CF patients homozygous for
the F508del mutation, albeit the health improvements are less than for individuals with G551D treated with ivacaftor (68, 75). Nevertheless, laboratory studies suggest that lumacaftor-ivacaftor combination therapy is likely to be beneficial to CF patients with a variety of rare missense mutations in CFTR (10, 29, 32).

To understand better the action of ivacaftor, here we investigated the temperature-dependence of wild-type and F508del-CFTR potentiation by the small molecule. Using excised inside-out membrane patches from cells expressing recombinant CFTR, we studied single-channel behavior over the temperature range 23 to 37 °C. As a control, we studied the benzimidazolone UC$_{CF}$-853, which potentiates CFTR by a different mechanism to ivacaftor (2, 13, 39, 51). Our results demonstrated that ivacaftor, but not UC$_{CF}$-853, robustly potentiates CFTR at all temperatures tested, restoring wild-type levels of channel activity (as measured by open probability ($P_o$)) to F508del-CFTR. They also revealed that ivacaftor abolishes the temperature-dependence of CFTR channel gating.

**METHODS**

**Cells and cell culture**

We used C127 mouse mammary epithelial cells and baby hamster kidney (BHK) cells stably expressing wild-type human CFTR and the F508del mutation (27, 46). Cells were generous gifts of CR O’Riordan (Sanofi Genzyme; C127 cells) and MD Amaral (University of Lisboa; BHK cells). Cells were cultured and used as described previously (60, 61) with the exception that the plasma membrane expression of F508del-CFTR was rescued by either low temperature incubation (27 °C for 72 – 96 h) or treatment with lumacaftor (3 μM for 24 – 48 h at 37 °C). The single-channel behavior of human CFTR in excised membrane patches from
different mammalian cell lines is equivalent (wild-type CFTR, (18); F508del-CFTR, Y Wang, Z Cai and DN Sheppard, unpublished observation).

**Patch-clamp experiments**

CFTR Cl\(^-\) channels were recorded in excised inside-out membrane patches using Axopatch 200A and 200B patch-clamp amplifiers and pCLAMP software (all from Molecular Devices, San Jose, CA, USA) (61). The pipette (extracellular) solution contained (mM): 140 N-methyl-D-glucamine (NMDG), 140 aspartic acid, 5 CaCl\(_2\), 2 MgSO\(_4\) and 10 N-tris[Hydroxymethyl]methyl-2-aminoethanesulphonic acid (TES), adjusted to pH 7.3 with Tris ([Cl\(^-\)], 10 mM). The bath (intracellular) solution contained (mM): 140 NMDG, 3 MgCl\(_2\), 1 CsEGTA and 10 TES, adjusted to pH 7.3 with HCl ([Cl\(^-\)], 147 mM; free [Ca\(^{2+}\)], < 10\(^{-8}\) M).

Using a temperature-controlled microscope stage (Brook Industries, Lake Villa, IL, USA), the temperature of the bath solution was varied between 23 and 37 °C.

After excision of inside-out membrane patches, we added the catalytic subunit of protein kinase A (PKA; 75 nM) and ATP (1 mM) to the intracellular solution within 2 minutes of membrane patch excision to activate CFTR Cl\(^-\) channels. To minimize channel rundown, we added PKA (75 nM), but not protein phosphatase inhibitors, to all intracellular solutions, maintained millimolar concentrations of ATP (wild-type CFTR, ≥ 0.3 mM; F508del-CFTR, 1 mM) in the intracellular solution and clamped voltage at −50 mV. The effects of temperature on the single-channel behavior of CFTR were tested by increasing the temperature of the intracellular solution from 23 to 37 °C in 3 – 4 °C increments. Once channel activity stabilized at the new test temperature, we acquired 4 – 10 minutes of single-channel data before increasing further the temperature and repeating the acquisition of data.

For wild-type CFTR, there was no difference in channel activity if temperature was decreased from 37 to 23 °C rather than increased from 23 to 37 °C. Because of the rundown of F508del-
CFTR at temperatures \(\geq 27\, ^\circ\text{C}\), we only studied F508del-CFTR by increasing temperature from 23 to 37 \(^\circ\text{C}\).

The effects of CFTR potentiators were tested by addition to the intracellular solution in the continuous presence of ATP (1 mM [F508del-CFTR] or 0.3 mM [wild-type]) and PKA (75 nM). We reduced the ATP concentration when testing the effects of potentiators on wild-type CFTR to avoid \(P_o\) saturation in the presence of potentiators. For wild-type CFTR, after acquiring control recordings at temperatures between 23 – 37 \(^\circ\text{C}\), test potentiators were added to the intracellular solution and once channel activity was stable, we acquired data with the test potentiator over the same temperature range. For UC\(_{CF}\)-853, but not ivacaftor (77), after washing the potentiator from the recording chamber, control data were acquired again between 23 – 37 \(^\circ\text{C}\). Because of the rundown of F508del-CFTR Cl\(^-\) channels in excised membrane patches at temperatures \(\geq 27\, ^\circ\text{C}\), data acquired under control conditions used different excised membranes patches from those used to acquire data in the presence of either UC\(_{CF}\)-853 or ivacaftor.

In this study, we used membrane patches containing \(\leq 5\) active channels (wild-type CFTR, number of active channels \((N) \leq 5\); F508del-CFTR, \(N \leq 5\)). To determine channel number, we used the maximum number of simultaneous channel openings observed during an experiment (16). To minimize errors, we used experimental conditions that robustly potentiate channel activity and verified that recordings were of sufficient length to ascertain the correct number of channels (72). Despite our precautions, we cannot exclude the possibility of unobserved F508del-CFTR Cl\(^-\) channels in excised membrane patches. Therefore, \(P_o\) values for F508del-CFTR might possibly be overestimated.
We recorded, filtered and digitized data as described previously (61). To measure single-channel current amplitude (i), Gaussian distributions were fit to current amplitude histograms. For \( P_o \) and burst analyses, lists of open- and closed-times were created using a half-amplitude crossing criterion for event detection and dwell-time histograms constructed as previously described (61); transitions < 1 ms were excluded from the analysis (eight-pole Bessel filter rise time \( T_{10-90} \sim 0.73 \text{ ms at } f_c = 500 \text{ Hz} \)). Histograms were fitted with one or more component exponential functions using the maximum likelihood method. For burst analysis, we used a \( t_c \) (the time that separates interburst closures from intraburst closures) determined from closed time histograms (wild-type CFTR: \( t = 23 \quad ^\circ\text{C}, \quad t_c = 22.5 \pm 2.5 \text{ ms (n = 6)} \); \( t = 37 \quad ^\circ\text{C}, \quad t_c = 15.3 \pm 0.5 \text{ ms (n = 6)} \); low temperature-rescued F508del-CFTR: \( t = 23 \quad ^\circ\text{C}, \quad t_c = 30.0 \pm 2.3 \text{ ms (n = 4)} \); \( t = 37 \quad ^\circ\text{C}, \quad t_c = 23.2 \pm 1.6 \text{ ms (n = 4)} \) (16)). The mean interburst interval \( (T_{IBI}) \) was calculated using Eq. 1 (see Ref. (16)):

\[
P_o = \frac{T_b}{(T_{MBD} + T_{IBI})},
\]

(Eq. 1)

where \( T_b = \text{(mean burst duration) x (open probability within a burst)} \). Mean burst duration \( (T_{MBD}) \) and open probability within a burst \( (P_{o(burst)}) \) were determined directly from experimental data using pCLAMP software. For wild-type CFTR, only membrane patches that contained a single active channel were used for burst analyses, whereas for F508del-CFTR, membrane patches contained no more than three active channels. We analyzed only bursts of F508del-CFTR single-channel openings with no superimposed openings that were separated from one another by a time interval > \( t_c \).

To evaluate the temperature-dependence of current flow and channel gating, we calculated \( Q_{10} \) temperature coefficients using Eq. 2 (see Ref. (47)):

\[
Q_{10} = \left( \frac{k_1}{k_2} \right) \left( \frac{10}{(t_1 - t_2)} \right)
\]

(Eq. 2)
where \( k_1 \) is the current amplitude or rate constant at temperature \( t_1 \), the higher temperature, and \( k_2 \) is the current amplitude or rate constant at temperature \( t_2 \), the lower temperature; all values of temperature for these calculations used the Kelvin scale. For the purpose of illustration, single-channel records were filtered at 500 Hz and digitized at 5 kHz before file size compression by 5-fold data reduction.

Reagents

The CFTR potentiator \( UC_{CF-853} \) (Cystic Fibrosis Foundation Therapeutics (CFFT) CFTR Compound Program reference no. P4) (13) was a generous gift of RJ Bridges (Rosalind Franklin University of Medicine and Science, Chicago, IL, USA) and CFFT (Bethesda, MD, USA), while ivacaftor and lumacaftor were purchased from Selleck Chemicals (Stratech Scientific Ltd., Newmarket, UK). PKA purified from bovine heart was purchased from Calbiochem (Merck Chemicals Ltd., Nottingham, UK). All other chemicals were of reagent grade and supplied by the Sigma-Aldrich Company Ltd. (Gillingham, UK).

ATP was dissolved in intracellular solution, while ivacaftor, lumacaftor and \( UC_{CF-853} \) were dissolved in DMSO. Stock solutions were stored at –20 °C except those of ATP, which were prepared freshly before each experiment. Immediately before use, stock solutions were diluted to final concentrations and, where necessary, the pH of the intracellular solution was re-adjusted to pH 7.3 to avoid pH-dependent changes in CFTR function (18). Precautions against light-sensitive reactions were observed when using CFTR modulators. DMSO was without effect on CFTR activity (61). On completion of experiments, the recording chamber was thoroughly cleaned before reuse (77).

Statistics
Data recording and analyses were randomized, but not blinded. Results are expressed as means ± SEM of n observations, but some group sizes were unequal due to technical difficulties with the acquisition of single-channel data. To test for differences between two groups of data acquired within the same experiment, we used Student’s paired t-test. To test for differences between multiple groups of data, we used an analysis of variance (ANOVA) followed by post-hoc tests. All tests were performed using SigmaPlot™ (version 13.0; Systat Software Inc., San Jose, CA, USA). Differences were considered statistically significant when $P < 0.05$. Data subjected to statistical analysis had n values ≥ 5 per group. In patch-clamp experiments, n represents the number of individual membrane patches obtained from different cells. To avoid pseudo-replication, all experiments were repeated at different times.

RESULTS

The single-channel activity of wild-type and F508del-CFTR is temperature-dependent

In this study, we investigated the temperature-dependence of wild-type and F508del-CFTR Cl⁻ channels and the effects of temperature on the action of the CFTR potentiators ivacaftor (67) and UC_{CF}-853 (P4; (13)). Using recombinant BHK and C127 cells and the excised inside-out configuration of the patch-clamp technique, we studied the single-channel behavior of CFTR between 23 and 37 °C by altering the temperature of the intracellular (bath) solution. For F508del-CFTR, all data were acquired while channel activity was stable prior to channel deactivation (49, 77).

Figure 1 shows representative recordings of wild-type and F508del-CFTR Cl⁻ channels following channel activation by PKA (75 nM) made in the presence of ATP (1 mM) in the intracellular solution, while Figure 2 quantifies the effects of temperature on current flow through open channels and the pattern of channel gating. To rescue the plasma membrane expression of F508del-CFTR, BHK cells expressing F508del-CFTR were either
incubated at 27 °C for 72 – 96 h or treated with the clinically-approved CFTR corrector lumacaftor (3 μM for 24 – 48 h at 37 °C). Consistent with previous results (for review, see Ref. (14)), Figures 1 and 2 demonstrate that the F508del mutation was without effect on current flow through CFTR Cl- channels in the full-open state, but perturbed channel gating (i, $P = 0.9; P_o, P < 0.001$; one-way ANOVA with Dunnett’s post-test). They also show that the single-channel behavior of F508del-CFTR rescued by low temperature or lumacaftor was equivalent. For both wild-type and F508del-CFTR, current flow through the full-open state increased 0.4-fold from 23 to 37 °C and $Q_{10}$ temperature coefficient values were comparable (Fig. 2A and Table 1).

The gating behavior of wild-type CFTR is characterized by bursts of channel openings interrupted by brief, flickery closures separated by longer closures between bursts (Fig. 1A). Consistent with previous results (5, 47), Figure 1A demonstrates that increasing the temperature of the intracellular solution had a marked impact on the gating pattern of wild-type CFTR. As temperature rose from 23 to 37 °C, the frequency of channel openings increased (as interburst interval [IBI] decreased 6.4-fold), but their duration decreased (as mean burst duration [MBD] diminished 0.9-fold) with the result that $P_o$ was enhanced 1.2-fold (Fig. 2B – D). At all temperatures tested, F508del-CFTR demonstrated a noticeably different pattern of channel gating compared to that of wild-type CFTR (Fig. 1). At 23 °C, the frequency of F508del-CFTR channel openings was reduced compared to those of wild-type, but their duration was increased, leading to a 2.8-fold lower $P_o$ than that of wild-type CFTR (Fig. 2B – D). As temperature rose from 23 to 37 °C, the frequency of F508del-CFTR channel openings increased, but their duration decreased, such that at 37 °C, the MBD of F508del-CFTR was 0.3-fold shorter than that of wild-type CFTR and its IBI was 6.3-fold longer with the result that the $P_o$ of F508del-CFTR was 10-fold lower than that of wild-type
CFTR (Fig. 2B – D). Consistent with previous results (42, 49), the data also show that there was no difference in the temperature-dependence of channel gating between F508del-CFTR Cl – channels rescued by low temperature incubation or treatment with lumacaftor (Fig. 2C and D). Thus, at both 23 and 37 °C, bursts of F508del-CFTR channel openings were very infrequent compared to those of wild-type CFTR. However, at 23 °C openings of F508del-CFTR were greatly prolonged, whereas at 37 °C they were reduced in length compared to those of wild-type CFTR (Fig. 1).

Interestingly, wild-type and F508del-CFTR exhibited strikingly different relationships between temperature and Pₒ. For wild-type CFTR, Pₒ values increased progressively between 23 and 37 °C (Fig. 2B). By contrast, F508del-CFTR rescued by either low temperature or lumacaftor exhibited a bell-shaped relationship between temperature and Pₒ with values increasing to a maximum around 30 °C after which they decreased to approach those recorded at 23 °C (Fig. 2B). Consistent with previous results (47), wild-type CFTR exhibited asymmetric Q₁₀ values for channel gating because the opening rate had ~3-fold greater temperature-dependence than the closing rate (Table 1). F508del-CFTR rescued by either low temperature or lumacaftor also had asymmetric Q₁₀ values for channel gating, albeit the difference in temperature-dependence of opening and closing rates was much less marked and not statistically significant for VX-809-rescued F508del-CFTR (P = 0.16; Student’s paired t-test) (Table 1).

**Potentiation of wild-type and F508del-CFTR by UC₉₅₃ is temperature-dependent**

To investigate the effects of temperature on CFTR potentiation by small molecules, we selected for study ivacaftor (67) and UC₉₅₃ (P4; (13)). Figure 3 shows representative recordings of wild-type and low temperature-rescued F508del-CFTR Cl – channels following the acute addition of UC₉₅₃ (10 μM) to the intracellular solution bathing excised...
membrane patches acquired at temperatures between 23 and 37 °C, while Figure 4 quantifies the action of UC_{CF}-853 on current flow and channel gating. To avoid saturation of the wild-type CFTR response in the presence of UC_{CF}-853, we reduced the ATP concentration in the intracellular solution to 0.3 mM. At all temperatures tested, UC_{CF}-853 was without effect on current flow through wild-type and F508del-CFTR Cl− channels in the full-open state (Figs. 3 and Fig. 4A and Table 1), albeit in these experiments there was a statistically significant difference in single-channel current amplitude between wild-type and low temperature-rescued F508del-CFTR (P < 0.001; one-way ANOVA with Dunnett’s post-test) (Fig. 4A).

Figure 3 demonstrates that for both wild-type and low temperature-rescued F508del-CFTR UC_{CF}-853 (10 μM) altered the temperature-dependence of channel gating. At all temperatures tested, UC_{CF}-853 enhanced 0.5 – 0.6-fold the P_o of wild-type CFTR with the result that the relationship between P_o and temperature was unaltered, but shifted to higher P_o values (Fig. 4B). Similarly, for low temperature-rescued F508del-CFTR, UC_{CF}-853 elevated P_o values at all temperatures tested, but it also shifted the maximal P_o recorded for F508del-CFTR from ~30 °C to ~33 °C with the result that the bell-shaped relationship between temperature and P_o was displaced upwards and to the right. Burst analysis of wild-type CFTR channel gating demonstrated that at all temperatures tested, UC_{CF}-853 (10 μM) elicited similar increases in the frequency (by reducing IBI 2.4-fold at 23 °C and 0.5-fold at 37 °C) and duration (by increasing MBD 0.3-fold at 23 °C and 0.5-fold at 37 °C) of channel openings (Fig. 4C and D). By contrast, the UC_{CF}-853-dependent enhancement of low temperature-rescued F508del-CFTR channel gating was achieved by increased frequency of channel openings (23 °C, 1.7-fold; 37 °C, 1.3-fold) (Fig. 4D). Except at 23 °C where UC_{CF}-853 (10 μM) reduced MBD, the small molecule had little or no effect on the duration of F508del-CFTR channel openings (Fig. 4C). Interestingly, Table 1 reveals that UC_{CF}-853 accentuated
the asymmetry in $Q_{10}$ values of channel gating for wild-type and F508del-CFTR by effects on
the temperature-dependence of the opening and closing rates.

**Ivacaftor potentiation of wild-type and F508del-CFTR is temperature-independent**

Next, we examined the temperature-dependence of CFTR potentiation by ivacaftor (67). Figure 5 shows representative recordings of wild-type and low temperature-rescued F508del-CFTR following acute addition of ivacaftor (10 μM) to the intracellular solution acquired at the indicated temperatures and Figure 6 summary data from 4 – 7 experiments. Like UC$_{CF}$-853 (Fig. 4A), ivacaftor did not alter current flow through wild-type and F508del-CFTR Cl$^-$ channels at each of the temperatures tested between 23 and 37 °C (Figs. 5 and 6A and Table 1).

At all temperatures tested, ivacaftor robustly enhanced the $P_o$ of wild-type and low temperature-rescued F508del-CFTR (Fig. 6B). Strikingly, the drug eliminated the temperature-dependence of $P_o$ for wild-type and F508del-CFTR Cl$^-$ channels with the result that at all temperatures tested, $P_o$ values of acutely potentiated wild-type CFTR were double those of acutely potentiated low temperature-rescued F508del-CFTR (Fig. 6B). At 37 °C, the $P_o$ value of low temperature-rescued F508del-CFTR was the same as that of wild-type CFTR in the absence of the drug, whereas at 23 °C, it was 0.4-fold larger than that of the wild-type CFTR control (Fig. 6B). Burst analysis revealed that ivacaftor acutely potentiated wild-type CFTR by increasing the frequency (by reducing IBI) and duration (by prolonging MBD) of channel openings (Fig. 6C and D). The data also reveal that the changes in MBD and IBI of wild-type CFTR were most marked at 23 °C, where MBD increased 1.9-fold and IBI decreased 3-fold (Fig. 6C and D). For low temperature-rescued F508del-CFTR, the major effect of ivacaftor was on the frequency of channel openings (by reducing IBI 4.7-fold at 23
and 2.1-fold at 37 °C) (Fig. 6D). However, at all temperatures tested ivacaftor prolonged channel openings by increasing MBD (Fig. 6C). Consistent with the drug’s effects on P₀, analysis of Q₁₀ values demonstrates that ivacaftor abolished the asymmetric temperature-dependence of channel gating (Table 1). For both wild-type and F508del-CFTR, the temperature-dependence of the opening and closing rates were equivalent in the presence of ivacaftor (Table 1).

To investigate further the action of ivacaftor, we studied the effects of nanomolar concentrations of ivacaftor and examined the consequences of treating lumacaftor-rescued F508del-CFTR Cl⁻ channels chronically with the drug. Because micromolar concentrations of ivacaftor destabilise F508del-CFTR (20, 48), we repeated our studies of wild-type CFTR using ivacaftor (100 nM). Figure 7 shows representative recordings acquired at the indicated temperatures for low temperature-rescued F508del-CFTR acutely treated with ivacaftor (100 nM) and summary data from 3 – 5 experiments. Comparison of single-channel records suggests that reducing the ivacaftor concentration was without effect on current flow through open channels, but modified channel gating (Figs. 5 – 7). An analysis of bursts revealed that there was little or no change in MBD on reducing the ivacaftor concentration from 10 μM to 100 nM (Fig. 7D). By contrast, IBI values were noticeably shorter with ivacaftor (100 nM), although the temperature-dependence of IBI resembled that observed using ivacaftor (10 μM) (Fig. 7E). As a result, ivacaftor (100 nM) also abolished the asymmetric temperature-dependence of channel gating (Table 1), while P₀ values were temperature-independent and 0.5-fold greater than those determined using ivacaftor (10 μM) (P = 0.14; one-way ANOVA with Dunnett’s post-test) (Fig. 7C).
Chronic ivacaftor treatment accentuates the thermoinstability of F508del-CFTR rescued by lumacaftor (21, 71). We therefore studied the temperature-dependence of lumacaftor-rescued F508del-CFTR treated chronically with ivacaftor at 27 and 37 °C only. Figure 8 shows representative recordings and Figure 9 summary data from 5 – 10 experiments. Chronic treatment with ivacaftor (1 μM) caused a small, albeit statistically significant (27 °C, P < 0.0001; 37 °C, P < 0.05) reduction in current flow through fully open F508del-CFTR Cl− channels at both 27 and 37 °C (Fig. 9A). By contrast, at both temperatures, the P_o of lumacaftor-rescued F508del-CFTR-treated chronically with ivacaftor exceeded that of low temperature-rescued F508del-CFTR treated acutely with the drug (Fig. 9B). As for acute treatment with the drug, the major effect of chronic ivacaftor treatment was to increase greatly the frequency of F508del-CFTR channel openings, although the drug also caused some prolongation of channel openings (Fig. 9C and D). Thus, through effects on the frequency and duration of channel openings, ivacaftor eliminates the temperature-dependence of CFTR activity.

DISCUSSION

This study investigated the temperature dependence of CFTR potentiation by ivacaftor and UC_CF-853. At all temperatures tested, ivacaftor and UC_CF-853 potentiated CFTR channel gating. However, potentiation by ivacaftor, but not UC_CF-853, abolished the temperature-dependence of channel gating for both wild-type and F508del-CFTR.

The temperature-dependence of current flow through wild-type CFTR resembles that of different ion channels, whereas the temperature-dependence of CFTR channel gating is greater than that of many different ion channels, but is similar to that of ATPases (for review, see Ref. (47)). Our own analyses of the temperature-dependence of wild-type CFTR concur
with the findings of Mathews et al. (47) and show that the opening rate of wild-type CFTR is ~3-fold more temperature-dependent than the closing rate. Of note, Mathews et al. (47) interpreted the asymmetric temperature-dependence of channel opening and closing as potential support for a cyclic gating scheme. Building on these and other data (e.g. (73, 74)), Csanády et al. (22) used the temperature-dependence of channel gating to propose an energetic profile for the irreversible gating cycle of CFTR. The authors’ analysis argues that channel opening proceeds as a wave of conformational change, which is initiated by formation of an ATP-bound NBD1:NBD2 dimer and then sweeps to the membrane-spanning domains (MSDs), leading to opening of the channel pore. By applying rate-equilibrium free-energy relationship analysis to the hydrolysis-deficient CFTR mutant D1370N, Sorum et al. (62) verified this model of channel opening and identified the interface between the NBDs and the MSDs as an energetic barrier to channel opening. Interestingly, the temperature-dependence of channel closure suggests that large scale protein movements are not required to close the CFTR pore (22). Instead, the hydrolysis of a single chemical bond in ATP bound at ATP-binding site 2 drives pore closure, which precedes partial disassembly of the NBD1:NBD2 dimer interface (22, 63, 65).

Analysis of the temperature-dependence of F508del-CFTR reveals that the mutant protein exhibits marked thermoinstability in excised membrane patches and planar lipid bilayers (3, 43, 49, 76). The irreversible loss of F508del-CFTR channel activity at 37 °C in the continuous presence of PKA and ATP involves both changes in channel gating and current flow through open channels (3, 49). Because revertant (second site) mutations in cis with F508del prevent the deactivation of F508del-CFTR Cl⁻ channels (4, 43, 76), the thermoinstability of F508del-CFTR is likely a consequence of structural defects not loss of anchoring to CFTR-interacting proteins (31). Previous studies of the temperature dependence
of F508del-CFTR prior to channel deactivation using the planar lipid bilayer technique show
that F508del-CFTR activity declines with increasing temperature (4, 8). The present studies
were performed under different experimental conditions using excised membrane patches.
They reveal that prior to channel deactivation, F508del-CFTR has a bell-shaped relationship
between temperature and $P_o$ with a maximum $P_o$ at ~30 °C, which is modulated by CFTR
potentiators. As for wild-type CFTR, the temperature-dependence of F508del-CFTR channel
gating was asymmetric, albeit the difference between the opening and closing rates was
greatly reduced and closure of the mutant channel required greater energy than wild-type
CFTR. This surprising result contrasts with previous work which shows that the F508del
mutation destabilizes the NBD1:NBD2 dimer (38).

Strikingly, the present results demonstrate that ivacaftor, but not UC9CF-853, eliminated
the temperature-dependence of CFTR channel gating. In the presence of ivacaftor, $P_o$ values
did not alter with increasing temperature and the temperature-dependence of channel gating
was lost. Because the channel opening rate shows greatest temperature sensitivity (47,
present study), the data suggest that the principal effect of ivacaftor is to promote channel
opening, particularly at temperatures ≤ 30 °C. Integrating these data with biochemical and
structural data, which demonstrated that ivacaftor reduces thermal stability (12, 49) and
increases conformational flexibility (21), argues that ivacaftor exerts its effects by
destabilizing a closed channel conformation. In addition, loss of the temperature-dependence
of channel gating suggests that ivacaftor might modify the irreversible cyclic gating scheme
of CFTR to favor a reversible one. Although this idea is only speculation, analysis of
ivacaftor’s action using the energetic coupling model of CFTR gating (40), demonstrated that
the drug promotes gating transitions that favor channel open states (37) as the present data
confirm. Of note, this analysis also provided an explanation for ivacaftor’s ability to promote both ATP-dependent and ATP-independent channel gating (26, 37).

The robust potentiation of CFTR channel gating achieved by ivacaftor confers wild-type levels of channel activity (as measured by $P_o$) on F508del-CFTR and other CF mutants once delivered to the plasma membrane ((58, 67, 77, 79); present study). However, it is important to emphasize that ivacaftor accelerates the deactivation of most, but not all, F508del-CFTR $Cl^-$ channels delivered to the plasma membrane by either low temperature or lumacaftor (21, 49, 71). In contrast to ivacaftor, at physiological temperatures, the benzimidazolone UC$_{CF}$-853 did not confer wild-type levels of channel activity on low temperature-rescued F508del-CFTR $Cl^-$ channels. This distinction between ivacaftor and UC$_{CF}$-853 might reflect the different potency and efficacy of a clinically-licensed drug and a screening hit (13, 67). Alternatively, it might reflect their diverse mechanisms of action. Al-Nakkash et al. (2) demonstrated that the benzimidazolones NS004 and NS1619 potentiate CFTR by a mechanism resembling that of genistein (34). Using the ATP-driven NBD dimerization model of CFTR channel gating (73, 74), Ai et al. (1) speculated that genistein might bind at the NBD1:NBD2 dimer interface and accelerate channel opening by lowering the free energy of the transition state, while slowing channel closure by stabilizing the binding of ATP at ATP-binding sites 1 and 2. Consistent with these ideas, Moran et al. (51) used virtual ligand docking with a molecular model of the NBD1:NBD2 dimer to suggest that genistein and UC$_{CF}$-853 bind at the dimer interface.

To date, the binding site for ivacaftor has not been identified. However, several lines of evidence argue that it is distinct from that of genistein, UC$_{CF}$-853 and other potentiators that interact with the NBDs (1, 2, 16). First, ivacaftor’s ability to potentiate ATP-independent gating, the drug’s lack of effect on the ATPase activity of CFTR and its potentiation of a...
CFTR construct missing NBD2 (26, 37, 78), argue persuasively that it does not interact with the ATP-binding sites. Second, ivacaftor potentiation of ΔR-CFTR, which lacks a large portion of the R domain (residues 634 – 836; (37)), demonstrates that the drug does not bind the R domain. Third, the accumulation of ivacaftor in the inner leaflet of the lipid bilayer and the reduced sensitivity of some CF mutations in the MSDs to potentiation by ivacaftor (9, 69), suggests that ivacaftor might exert its effects by interacting with the MSDs. Such a site of action supports the drug’s effects on the kinetics of channel gating (37). Using hydrogen/deuterium exchange mass spectroscopy, Byrnes et al. (12) investigated ivacaftor binding to a human CFTR construct with thermostabilizing mutations that themselves modify CFTR channel gating (4, 57). Intriguingly, ivacaftor bound to multiple sites on this CFTR construct, including the Lasso motif (80), transmembrane segment 2 in MSD1, the coupling helices of intracellular loops 1, 3 and 4 and NBD2 with tightest binding located at the MSD2-NBD1 and MSD2-NBD2 interfaces (12). These data suggest that ivacaftor might bind near F508 in a region overlapping the small molecule-binding sites identified by Kalid et al. (41) at the interface of the NBDs with the MSDs. Nevertheless, virtual ligand docking data suggest other potential binding sites for ivacaftor including one at the NBD1:NBD2 interface in the partially unfolded structure of F508del-CFTR (71).

Most studies of CFTR function using the patch-clamp technique are conducted at room temperature (~23 °C). An advantage of working at room temperature is that the kinetics of CFTR channel gating are slowed, permitting the resolution of short-lived gating transitions that are challenging to detect at 37 °C (e.g. (36)). However, studying mutant CFTR at room temperature might preclude full understanding of the mechanism of CFTR dysfunction. For example, channel deactivation or rundown, one measure of the plasma membrane instability of CF mutants, is best observed at temperatures ≥ 30 °C, (3, 43, 49, 76, 77). Moreover, the
present results show that at 23 °C, the rate of F508del-CFTR channel closure is markedly slowed compared to wild-type CFTR, whereas at 37 °C, it is equivalent to that of wild-type CFTR or even faster, hinting at instability of the open channel conformation, possibly the interaction of ATP with ATP-binding site 2 (38, 74). Although we have not evaluated directly the temperature-dependence of other CF mutants, comparison of our own data with those of other investigators suggests that temperature influences their gating behavior (e.g. N1303K-CFTR (25, 32)). Differences in temperature also likely explain inconsistencies in the published literature on CFTR modulators. Previous work showed that the non-hydrolysable ATP analogue AMP-PNP locked CFTR Cl− channels in the open configuration at temperatures ≤ 30 °C, but at temperatures ≥ 30 °C, locking events were seldom observed, if at all (17, 47). Future studies of new CFTR potentiators should include assessment of their temperature-dependence to assist the identification of small molecules with therapeutic potential.

Although body temperature is normally tightly controlled, fluctuations occur during fever and chills, symptoms associated with pulmonary exacerbations in CF (30). Previous work suggests that body temperature and metabolic activity might influence CFTR behavior (11). This idea might explain the different effects of temperature on the single-channel activity of human CFTR observed in the present study and the CFTR-mediated Cl− conductance of intact microperfused human sweat ducts, which achieved maximal activity around 30 °C (53). Alternatively, or in addition, differences in the experimental conditions used to study recombinant CFTR in excised membrane patches and native CFTR in intact sweat ducts might provide an explanation. Because the cellular ATP concentration exceeds the $K_m$ (substrate concentration required for half maximal activity) for CFTR regulation by ATP and inhibition by ADP is likely to be weak at cellular concentrations (6, 7, 64), the
balance of protein kinase and phosphatase activity predominantly controls CFTR activity in vivo (28). This highlights the therapeutic potential of small molecules that promote the phosphorylation of CFTR by PKA (e.g. RPL554; (66)). Importantly, following CFTR phosphorylation by PKA, ivacaftor potentiates both ATP-dependent and ATP-independent CFTR channel gating (26, 37), highlighting its value in the treatment of CF (54, 59).

In conclusion, wild-type and, to a much reduced extent, F508del-CFTR demonstrate asymmetric temperature-dependence of channel gating with the opening rate exhibiting greater temperature sensitivity than the closing rate. Ivacaftor robustly potentiates CFTR at all temperatures tested, restoring wild-type levels of channel activity to F508del-CFTR and abolishing the temperature-dependence of CFTR channel gating. Thus, temperature has the potential to influence markedly the gating pattern of CF mutants and the action of small molecule CFTR modulators.
AUTHOR CONTRIBUTIONS

Conception and design of the experiments: D.N.S.; performed the research: Y.W.; analysis and interpretation of data: Y.W., Z.C., M.G. and D.N.S.; drafting the article or revising it critically for important intellectual content: Y.W and D.N.S. All authors approved the final version of the manuscript.

CONFLICT OF INTEREST

M.G. is Chief Scientific Officer of Enterprise Therapeutics. The other authors declare that they have no conflicts of interest with the contents of this article.

ACKNOWLEDGEMENTS

We thank MD Amaral, CR O’Riordan, RJ Bridges and CFFT for generous gifts of recombinant cells and the small molecule UC\textsubscript{CF}-853 (P4). We are very grateful to our laboratory colleagues for valuable discussions and assistance. This work was funded by Cystic Fibrosis Foundation Therapeutics and the Cystic Fibrosis Trust. YW was supported by a scholarship from Beijing Sun-Hope Intellectual Property Ltd.
REFERENCES


FIGURE LEGENDS

Figure 1: Temperature-dependence of wild-type and F508del-CFTR single-channel activity  
A–C: Representative recordings of wild-type and F508del-CFTR Cl\(^-\) channels in excised inside-out membrane patches from recombinant BHK cells. The plasma membrane expression of F508del-CFTR was rescued by either low temperature incubation (27 °C for 72 – 96 h) (B) or treatment with lumacaftor (VX-809; 3 µM) for 24 – 48 h at 37 °C (C). The recordings were acquired at the indicated temperatures in the presence of ATP (1 mM) and PKA (75 nM) in the intracellular solution. Dotted lines indicate where channels are closed and downward deflections correspond to channel openings. In this and subsequent figures, a large Cl\(^-\) concentration gradient was imposed across membrane patches ([Cl\(^-\)]\(_{\text{int}}\), 147 mM; [Cl\(^-\)]\(_{\text{ext}}\), 10 mM) and membrane voltage was clamped at −50 mV to magnify the size of channel openings.

Figure 2: Analysis of the temperature-dependence of wild-type and F508del-CFTR Cl\(^-\) channels  
A–D: Summary data show the change in single-channel current amplitude (i), open probability (P\(_o\)), mean burst duration (MBD) and interburst interval (IBI) between 23 and 37 °C for wild-type CFTR and F508del-CFTR rescued by either low temperature incubation (27 °C for 72 – 96 h) or lumacaftor (VX-809; 3 µM) for 24 – 48 h at 37 °C). Data are means ± SEM (wild-type, A–B, n = 5 – 9, C–D, n = 5 – 6; 27 °C-rescued F508del-CFTR, A–B, n = 5 – 13, C–D, n = 4 – 9; VX-809-rescued F508del-CFTR, A–B, n = 7 – 9, C–D, n = 5 – 8). In A, the continuous lines are the fit of first-order regression functions to mean data, whereas in B–D, they are the fit of second-order regression functions to mean data.

Figure 3: Temperature-dependence of wild-type and F508del-CFTR potentiation by the small molecule UC\(_{\text{CF}}\)-853  
A–C: Representative recordings of wild-type and low
temperature-rescued F508del-CFTR Cl⁻ channels in excised inside-out membrane patches from recombinant BHK cells acquired at the indicated temperatures to show the effects of UC₉₅-853 (P₄; 10 µM) addition to the intracellular solution. For wild-type CFTR, ATP (0.3 mM) and PKA (75 nM) were continuously present in the intracellular solution, whereas for low temperature-rescued F508del-CFTR, ATP (1 mM) and PKA (75 nM) were used. For low temperature-rescued F508del-CFTR recordings acquired in the absence of P₄, see Figure 1. Dotted lines indicate where channels are closed and downward deflections correspond to channel openings.

Figure 4: Analysis of the temperature-dependence of wild-type and F508del-CFTR potentiation by UC₉₅-853 A–D: Summary data show the change in single-channel current amplitude (i), open probability (Pₒ), mean burst duration (MBD) and interburst interval (IBI) between 23 and 37 °C for wild-type and low temperature-rescued F508del-CFTR in the absence and presence of UC₉₅-853 (P₄; 10 µM) in the intracellular solution. Data are means ± SEM (wild-type, A–B, n = 5–8, C–D, n = 4–5; 27 °C-rescued F508del-CFTR, A–B, n = 4–8, C–D, n = 3–5). In A, the continuous lines are the fit of first-order regression functions to mean data, whereas in B–D, they are the fit of second-order regression functions to mean data.

Figure 5: The effects of temperature on wild-type and F508del-CFTR potentiation by ivacaftor A and B: Representative recordings of wild-type CFTR and low temperature-rescued F508del-CFTR in excised inside-out membrane patches from recombinant BHK cells acquired at the indicated temperatures to show the effects of acute addition of ivacaftor (VX-770; 10 µM) to the intracellular solution. For wild-type CFTR, ATP (0.3 mM) and PKA (75 nM) were continuously present in the intracellular solution, whereas for F508del-CFTR, ATP
(1 mM) and PKA (75 nM) were used. For control recordings acquired in the absence of ivacaftor, see Figure 3 for wild-type CFTR and Figure 1 for low temperature-rescued F508del-CFTR. Dotted lines indicate where channels are closed and downward deflections correspond to channel openings.

**Figure 6: Analysis of the temperature-dependence of wild-type and F508del-CFTR potentiation by ivacaftor**  
*A–D*: Summary data show the change in single-channel current amplitude (*i*), open probability (*P_o*), mean burst duration (MBD) and interburst interval (IBI) between 23 and 37 °C for wild-type and low temperature-rescued F508del-CFTR in the absence and presence of ivacaftor (VX-770; 10 μM) added acutely to the intracellular solution. Data are means ± SEM (wild-type, *A–B*, n = 5 – 7, *C–D*, n = 4 – 6; 27 °C-rescued F508del-CFTR, n = 4 – 7). In *A*, the continuous lines are the fit of first-order regression functions to mean data, whereas in *B–D*, they are the fit of second-order regression functions to mean data.

**Figure 7: The temperature-dependence of F508del-CFTR potentiated by nanomolar concentrations of ivacaftor**  
*A*: Representative recordings of low temperature-rescued F508del-CFTR in an inside-out membrane patch excised from a recombinant BHK cell acquired at the indicated temperatures to show the effects of acute addition of ivacaftor (VX-770; 100 nM) to the intracellular solution. The recordings were made in the continuous presence of ATP (1 mM) and PKA (75 nM) in the intracellular solution. For control recordings acquired in the absence of ivacaftor, see Figure 1. Dotted lines indicate where channels are closed and downward deflections correspond to channel openings.  
*B–E*: Summary data show the change in single-channel current amplitude (*i*), open probability (*P_o*), mean burst duration (MBD) and interburst interval (IBI) between 23 and 37 °C for low
temperature-rescued F508del-CFTR potentiated by ivacaftor (VX-770; 100 nM). Data are means ± SEM (B–C, n = 4 – 5; D–E, n = 3 – 4). In B and C, the continuous lines are the fit of first-order regression functions to mean data, whereas in D and E, they are the fit of second-order regression functions to mean data. For control data acquired in the absence of ivacaftor, see Figure 6.

**Figure 8: Potentiation of lumacaftor-rescued F508del-CFTR Cl—channels by chronic treatment with ivacaftor**  
A and B: Representative recordings of wild-type and F508del-CFTR rescued by either low temperature incubation or treatment with lumacaftor (VX-809; 3 μM) in excised inside-out membrane patches from recombinant BHK cells acquired at either 27 °C (A) or 37 °C (B) to show the effects of acute (aVX-770; 10 μM) and chronic (cVX-770; 1 μM) ivacaftor treatment. ATP (1 mM) and PKA (75 nM) were continuously present in the intracellular solution. Dotted lines indicate where channels are closed and downward deflections correspond to channel openings.

**Figure 9: Chronic ivacaftor potentiates robustly lumacaftor-rescued F508del-CFTR Cl—channels at 27 and 37 °C**  
A–D: Summary data show the single-channel current amplitude (i), open probability (P_o), mean burst duration (MBD) and interburst interval (IBI) at 27 and 37 °C for wild-type CFTR and lumacaftor (VX-809)-rescued F508del-CFTR treated either acutely (aVX-770; 10 μM) or chronically (cVX-770; 1 μM) with ivacaftor. Data are means ± SEM (wild-type: A–B, n = 6 – 10, C–D, n = 6; 27 °C-rescued F508del-CFTR: control, A–B, n = 10 – 14, C–D, n = 9; aVX-770, A–B, n = 4 – 5, C–D, n = 4; VX-809-rescued F508del-CFTR: control A–B, n = 7 – 8, C–D, n = 5 – 6; aVX-770, A–B, n = 4 – 8, C–D, n = 4 – 6; cVX-770, A–B, n = 9 – 10, C–D, n = 4 – 5); *, P < 0.05 vs. wild-type CFTR; †, P < 0.05 vs. F508del-CFTR; ‡, P < 0.05 vs. F508del-CFTR, VX-809.
Table 1: Temperature coefficients of wild-type and F508del-CFTR

<table>
<thead>
<tr>
<th>Conditions</th>
<th>Temperature coefficient (Q_{10}) values</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>i</td>
</tr>
<tr>
<td>WT CFTR</td>
<td></td>
</tr>
<tr>
<td>(1 mM ATP)</td>
<td>1.39 ± 0.04</td>
</tr>
<tr>
<td>(0.3 mM ATP)</td>
<td>1.37 ± 0.05</td>
</tr>
<tr>
<td>(0.3 mM ATP + P4)</td>
<td>1.35 ± 0.03</td>
</tr>
<tr>
<td>(0.3 mM ATP + VX-770)</td>
<td>1.39 ± 0.02</td>
</tr>
<tr>
<td>F508del-CFTR; 27 °C-rescued</td>
<td>1.53 ± 0.03</td>
</tr>
<tr>
<td>F508del-CFTR; VX-809-rescued</td>
<td>1.54 ± 0.05</td>
</tr>
<tr>
<td>F508del-CFTR; 27 °C-rescued; P4</td>
<td>1.35 ± 0.04</td>
</tr>
<tr>
<td>F508del-CFTR; 27 °C-rescued; VX-770 (10 μM)</td>
<td>1.50 ± 0.06</td>
</tr>
<tr>
<td>F508del-CFTR; 27 °C-rescued; VX-770 (100 nM)</td>
<td>1.30 ± 0.02</td>
</tr>
</tbody>
</table>

Temperature coefficient (Q_{10}) values for single-channel current amplitude (i), channel opening rate and channel closing rate of wild-type and F508del-CFTR calculated from mean values of single-channel current amplitude, IBI and MBD for the indicated experimental conditions; UC_{CF}-853 was tested at 10 μM and ivacaftor at 100 nM (F508del-CFTR only) or 10 μM. Data are means ± SEM (n = 4, except wild-type CFTR (0.3 and 1 mM ATP) and VX-809-rescued F508del-CFTR, where n = 5); *, P < 0.05 vs. opening rate. For low temperature-rescued F508del-CFTR in the absence and presence of UC_{CF}-853, channel deactivation at 37 °C prevented collection of sufficient data to determine Q_{10} values for opening and closing rates. Abbreviations: P4, UC_{CF}-853; VX-770, ivacaftor; VX-809, lumacaftor.
Figure 1

(A) WT

1 mM ATP

23 °C

27 °C

30 °C

33 °C

37 °C

1 pA

Time (s)

(B) F508del

27 °C, 1 mM ATP

23 °C

27 °C

30 °C

33 °C

37 °C

1 pA

Time (s)

(C) VX-809, 1 mM ATP

23 °C

27 °C

30 °C

33 °C

37 °C

1 pA

Time (s)
Figure 2
Figure 4

A. 

B. 

C. 

D. 

WT, Control

WT, P4

F508del, 27 °C

F508del, 27 °C, P4
Figure 5

WT

0.3 mM ATP, VX-770

23 °C

27 °C

30 °C

33 °C

37 °C

1 pA

Time (s)

B

27 °C, 1 mM ATP, VX-770

23 °C

27 °C

30 °C

33 °C

37 °C

1 pA

Time (s)
Figure 6
Figure 7

A F508del, VX-770 (100 nM) 23 ºC

B

C

D

E

1 pA

Time (s)

T (ºC)

T (ºC)

T (ºC)

T (ºC)

Figure 7
Figure 9